Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor
Matthew Pakizegee, PharmD, MS
Jonathan W Hodgson, MBA
Chad McAuliffe
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD),...